Project Grant R01HL174477
- This $423,000 Project Grant was awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the direct regulation of cell cycle genes by cell identity factors during myeloid differentiation. Specifically, the project aims to determine how transcription factors PU.1 and C/EBP regulate the expression of cyclin-dependent kinase inhibitors and cyclin D2 to induce cell cycle...
- This federal Project Grant award of $225,101 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research to investigate the mechanisms underlying the increased risk of hematological malignancies in sickle cell disease patients. The key objectives of this 2-year project are to: 1) Perform experiments to understand how increased oxidative stress and DNA damage in hematopoietic stem and progenitor cells lead to the development of clonal...
- This five-year $360,281 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Biology Research program (CFDA 93.396). The grantee, Washington University, will conduct studies to define the contribution of altered epigenetic patterns and genome organization to the pathogenesis of acute myeloid leukemia (AML). Researchers will perform comprehensive epigenetic analysis of DNA methylation and three-dimensional...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded a Project Grant of $151,040 to Harvard Medical School (operating through Harvard College's Office of Research Administration) beginning January 8, 2026, with completion targeted for December 31, 2028. This award supports research training and scientific investigation into the direct mechanisms of N6-methyladenosine (M6A) deposition on messenger RNA (mRNA) and...
- This R03 project grant, awarded by the National Center for Advancing Translational Sciences (NCATS) under CFDA Program 93.350, aims to comprehensively identify metabolic enzymes that control the generation of TCF1+ progenitor CD8+ T cells, which are critical for durable anti-tumor immune responses. The $169,500 award, spanning from September 1, 2024 to August 31, 2026, will fund two key research objectives: Identifying metabolic enzymes whose loss alters T cell differentiation and the TCF1+...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Columbia University's Health Sciences Division a $1,394,592 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) on August 5, 2025, with completion targeted for March 31, 2026. This research initiative investigates epitranscriptomic regulation of hematopoietic stem cell (HSC) niche generation and regeneration, focusing on the role of N6-methyladenosine (M6A) mRNA modifications in...
- This $693,942 National Institutes of Health National Heart Lung and Blood Institute Project Grant funds research at Northwestern University aimed at elucidating epigenetic modifiers of regulatory T cell function following viral pneumonia. The goal is to establish causal links between DNA methyltransferase activity, the DNMT adapter UHRF1, and DNA hypermethylation signatures in regulatory T cells during aging and their impaired reparative function after severe viral pneumonia. Through three...
- This $683,472 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Cincinnati to develop a novel targeted therapy for acute myeloid leukemia (AML). The key objectives are to therapeutically target the DHODH enzyme to induce AML cell differentiation, activate the immune system, and induce ferroptosis-mediated cell death. This approach aims to better differentiate AML cells from normal hematopoietic stem cells and enhance...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $462,454 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective August 8, 2025, with completion targeted for June 30, 2027. The award funds research to characterize DNA methylation (5MC) dynamics in trisomy 21 (Down syndrome)-associated hematopoiesis and leukemia. The project will deliver single-cell...
- This Project Grant award of $442,750, funded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports fundamental research into the regulation of histone lysine methyltransferase (HLMT) substrates. Awarded to Virginia Polytechnic Institute & State University on August 1, 2025, with a completion date of June 30, 2030, the research addresses critical gaps in understanding how cells maintain epigenetic...
CRITICAL ROLES OF RNA M5C-MBD6-H2AK119UB DEUBIQUITYLATION AXIS IN TET2-MEDIATED HSC REGULATION - ABSTRACT TET2 IS COMMONLY MUTATED IN ADULT MYELOID MALIGNANCIES AND NORMAL INDIVIDUALS WITH CLONAL HEMATOPOIESIS. TET2 PLAYS AN IMPORTANT ROLE IN THE REGULATION OF HEMATOPOIETIC STEM/PROGENITOR CELLS (HSCS/HPCS; HSPCS) AS TET2 LOSS LEADS TO HALLMARK HSC SELF-RENEWAL ENHANCEMENT WITH SKEWED DIFFERENTIATION TOWARDS MONOCYTIC LINEAGE. BESIDES DNA 5-METHYLCYTOSINE (5MC), TET2 ALSO CATALYZES RNA 5-METHYLCYTOSINE (M5C) OXIDATION. THE CATALYTIC ACTIVITY OF TET2 IS REQUIRED FOR NORMAL HSPC FUNCTION, WE THEREFORE SPECULATE THAT THE ENZYMATIC ACTIVITY OF TET2 ON RNA ALSO CONTRIBUTES TO HSPC REGULATION. INDEED, TET2 CAN CONTROL CHROMATIN STATE AND TRANSCRIPTION BY BINDING TO AN RNA-BINDING PROTEIN PSPC1 AND MODULATING RNA M5C OXIDIZATION IN MOUSE EMBRYONIC STEM CELLS (MESCS). STIMULATED BY A RECENT STUDY DISCOVERING A NOVEL MECHANISM OF CHROMATIN REGULATION THROUGH REVERSIBLE N6-METHYLADENOSINE MODIFICATION ON CHROMATIN-ASSOCIATED RNA (CARNA), WE EXPLORED THE POTENTIAL CHROMATIN REGULATION THROUGH THE TET2-MEDIATED CARNA M5C OXIDATION, WHICH LED TO THE FOLLOWING EXCITING FINDINGS: (I) TET2 OXIDIZES M5C ON CARNAS TO HM5C (5-HYDROXYMETHYLATION ) WITH LONG TERMINAL REPEAT (LTR) RNAS AS THE MAIN SUBSTRATES. (II) MBD6 IS A SPECIFIC RNA M5C READER PROTEIN AND NSUN2 IS A MAIN M5C WRITER PROTEIN FOR CARNAS. (III) MBD6, VIA BINDING TO M5C-MODIFIED LTR RNAS, RECRUITS H2AK119UB DEUBIQUITYLASE COMPLEX TO MEDIATE LOCAL CHROMATIN ACTIVATION IN MESCS. BASED ON THESE FINDINGS, WE HYPOTHESIZE THAT TET2 EXERTS ITS REGULATORY FUNCTION IN HSPCS MAINLY THROUGH CARNA M5C OXIDATION, AND DEREGULATION OF CARNA M5C- MBD6-H2AK119UB DEUBIQUITYLATION AXIS UPON TET2 LOSS/MUTATION LEADS TO ALTERED HSPC GENE EXPRESSION AND FUNCTION. TO TEST OUR HYPOTHESIS, WE WILL: (1) DEFINE THE IMPORTANCE OF TET2-MEDIATED CARNA M5C OXIDATION IN THE REGULATION OF HSPC FUNCTION. WE WILL FIRST IDENTIFY IN HSPCS THE KEY CARNAS WITH ALTERED M5C METHYLATION UPON TET2 LOSS AND CORELATE WITH LOCAL GENE EXPRESSION. WE WILL THEN EXAMINE THE IMPACT OF CARNA M5C DEREGULATION ON TET2 DEFICIENCY-MEDIATED ABNORMAL HSPC FUNCTION AND GENE EXPRESSION BY USING NSUN2 KNOCKOUT (NORMALIZE THE CARNA M5C INCREASES UPON TET2-LOSS) AS WELL AS TARGETED DEMETHYLATION (WITH DCAS13RX-TET2CD) AND METHYLATION BLOCKAGE (WITH STERIC ANTI-SENSE OLIGO) OF INDIVIDUAL TET2 LTR RNA TARGET. (2) INVESTIGATE THE SIGNIFICANCE OF RNA M5C READER, MBD6, IN TET2-MEDIATED REGULATION OF HSPC BY EXAMINING THE IMPACT OF MBD6 LOSS ON TET2 DEFICIENCY-MEDIATED HALLMARK ABNORMAL HSPC FUNCTION AND GENE EXPRESSION. 3) VALIDATE THE ROLES OF CARNA M5C-MBD6-H2AK119UB DEUBIQUITYLATION AXIS IN HUMAN HSPCS. WE WILL ALSO INVESTIGATE WHETHER MUTATIONS OF TET2 IMPAIR CARNA M5C-MBD6-H2AK119UB DEUBIQUITYLATION AXIS IN HSPCS FROM TET2-MUTATED MYELOID MALIGNANCIES. THE SENSITIVITY OF TET2-MUTATED VS. TET2-WT HSPCS TO MBD6 OR NSUN2 LOSS WILL ALSO BE ACCESSED. SUCCESS OF THE PROPOSED STUDIES WILL GAIN FUNDAMENTAL KNOWLEDGE ON HSPC BIOLOGY BY ESTABLISHING CARNA M5C-MBD6-H2AK119UB DEUBIQUITYLATION AXIS AS A CRITICAL AND NOVEL PATHWAY FOR TET2-MEDIATED HSPC REGULATION. THESE STUDIES CAN LEAD TO NOVEL STRATEGIES TO TARGET TET2-MUTATED HSPCS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $703.0k | 6/6/25 | ||
| Not listed | $717.4k | 5/10/24 | ||
| Not listed | $717.4k | 5/10/24 |